| 货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
|---|---|---|---|---|
| U614669-5mg |
5mg |
期货  |
| |
| U614669-25mg |
25mg |
期货 |
|
| 别名 | 乌帕莫司他 |
|---|---|
| 英文别名 | WX-671 |
| 规格或纯度 | Moligand™ |
| 英文名称 | upamostat |
| 作用类型 | 抑制剂 |
| 作用机制 | 纤溶酶原激活物抑制剂；尿激酶 |
| 分子类型 | 小分子 |
|---|---|
| IIUPAC Name | ethyl 4-[(2S)-3-[3-[(Z)-N'-hydroxycarbamimidoyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate |
| INCHI | 1S/C32H47N5O6S/c1-8-43-32(39)37-14-12-36(13-15-37)31(38)28(17-23-10-9-11-24(16-23)30(33)34-40)35-44(41,42)29-26(21(4)5)18-25(20(2)3)19-27(29)22(6)7/h9-11,16,18-22,28,35,40H,8,12-15,17H2,1-7H3,(H2,33,34)/t28-/m0/s1 |
| InChi Key | HUASEDVYRABWCV-NDEPHWFRSA-N |
| Smiles | CCOC(=O)N1CCN(CC1)C(=O)C(CC2=CC(=CC=C2)C(=NO)N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C |
| Isomeric SMILES | CCOC(=O)N1CCN(CC1)C(=O)[C@H](CC2=CC(=CC=C2)/C(=N/O)/N)NS(=O)(=O)C3=C(C=C(C=C3C(C)C)C(C)C)C(C)C |
| PubChem CID | 9830667 |
| MeSH Entry Terms | Mesupron;RHB-107;upamostat;WX-671 |
| 分子量 | 629.800 g/mol |
|---|---|
| XLogP3 | 5.000 |
| 氢键供体数Hydrogen Bond Donor Count | 3 |
| 氢键受体数Hydrogen Bond Acceptor Count | 8 |
| 可旋转键计数Rotatable Bond Count | 12 |
| 精确质量Exact Mass | 629.325 Da |
| 单同位素质量Monoisotopic Mass | 629.325 Da |
| 拓扑极表面积Topological Polar Surface Area | 163.000 Ų |
| 重原子数Heavy Atom Count | 44 |
| 形式电荷Formal Charge | 0 |
| 复杂度Complexity | 1070.000 |
| 同位素原子数Isotope Atom Count | 0 |
| 定义的原子立体中心计数Defined Atom Stereocenter Count | 1 |
| 未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
| 定义的键立体中心计数Defined Bond Stereocenter Count | 1 |
| 未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
| 所有立体化学键的总数The total count of all stereochemical bonds | 1 |
| 共价键合单元计数Covalently-Bonded Unit Count | 1 |
| 1. Ertongur S, Lang S, Mack B, Wosikowski K, Muehlenweg B, Gires O. (2004) Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.. Int J Cancer, 110 (6): (815-24). [PMID:15170662] |
| 2. Setyono-Han B, Stürzebecher J, Schmalix WA, Muehlenweg B, Sieuwerts AM, Timmermans M, Magdolen V, Schmitt M, Klijn JG, Foekens JA. (2005) Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1.. Thromb Haemost, 93 (4): (779-86). [PMID:15841327] |
| 3. Meyer JE, Brocks C, Graefe H, Mala C, Thäns N, Bürgle M, Rempel A, Rotter N, Wollenberg B, Lang S. (2008) The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.. Breast Care (Basel), 3 (s2): (20-24). [PMID:20824010] |
| 4. Froriep D, Clement B, Bittner F, Mendel RR, Reichmann D, Schmalix W, Havemeyer A. (2013) Activation of the anti-cancer agent upamostat by the mARC enzyme system.. Xenobiotica, 43 (9): (780-4). [PMID:23379481] |
| 5. Heinemann V, Ebert MP, Laubender RP, Bevan P, Mala C, Boeck S. (2013) Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer.. Br J Cancer, 108 (4): (766-70). [PMID:23412098] |
首页
400-620-6333
